One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
CureVac N.V. logo
CureVac N.V. CVAC
report update icon

Quarterly report 2025-Q2
added 06-06-2026

CureVac N.V. Cash Flow 2024-2011 | CVAC

Brief overview of CureVac N.V.'s cash movements

Cash flows are assessed across five available annual periods spanning 2020 to 2024.

Core cash generation deteriorated, ending at €101.9 million versus €522.4 million at the beginning.

Only 2 of five annual observations were positive, indicating weak repeatability.

Overall picture

Taken together, CureVac N.V.'s cash flow indicators point to increased dependence on reserves or outside financing.

Annual Cash Flow CureVac N.V.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

102 M -268 M -286 M -733 M 522 M -87 M -74.1 M - - - - - - -

All numbers in EUR currency

Quarterly Cash Flow CureVac N.V.

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-83.4 M -41.4 M 102 M 168 M -186 M -96.6 M -268 M -224 M -164 M -99.6 M -286 M - - -137 M - - - -197 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Cash Flow Statement is one of the three key financial reports of the company CureVac N.V., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
- 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
- - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
- 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
- - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
- - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
Galecto Galecto
GLTO
- - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Novavax Novavax
NVAX
$ 10.83 10.69 % $ 1.75 B usaUSA
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
- - $ 18.8 M usaUSA
IMARA IMARA
IMRA
- 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
- 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
- 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
Verastem Verastem
VSTM
$ 8.55 -8.85 % $ 593 M usaUSA
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA